SCHEMBL29501264

SCHEMBL29501264

FC(F)(F)COc1ncccc1-c1cccc(Cl)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SCN9A Q15858 1/20 0.53
▸ KCNH2 Q12809 1/20 0.41
▸ SCN5A Q14524 1/20 0.41
▸ SCN2A Q99250 1/20 0.41
▸ SCN10A Q9Y5Y9 1/20 0.41
▸ PDE4A P27815 2/20 0.40
▸ PDE4C Q08493 2/20 0.40
▸ PDE4D Q08499 2/20 0.40
▸ RORC P51449 1/20 0.40
▸ GPBAR1 Q8TDU6 1/20 0.40
▸ KDR P35968 2/20 0.39
▸ NUDT1 P36639 3/20 0.38
▸ XPO1 O14980 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ DHFR P00374 1/20 0.38
▸ PDE4B Q07343 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29501252 0.81 TDO2 (0.38) SCN9ASCN5APDE4APDE4CPDE4D
SCHEMBL16113533 0.80 PTGS2 (0.41) SCN9AKCNH2SCN5ASCN2ASCN10A
SCHEMBL16113418 0.79 PTGS2 (0.40) SCN9AKDRNUDT1XPO1MEN1
SCHEMBL28045812 0.78 KMT2A (0.42) SCN9APDE4APDE4CPDE4DNUDT1
SCHEMBL16114414 0.78 PTGS2 (0.42) RORCNUDT1MEN1GAAMAPT
SCHEMBL29501242 0.78 LOXL2 (0.47) PDE4APDE4CPDE4DNUDT1MAPT
SCHEMBL15676581 0.78 LOXL2 (0.47) PDE4APDE4CPDE4DNUDT1MAPT
SCHEMBL29501216 0.77 TRPV4 (0.46) PDE4APDE4CPDE4DKDRNUDT1
SCHEMBL29501234 0.74 ALOX5AP (0.52) KCNH2PDE4APDE4CPDE4DKDR
SCHEMBL945750 0.74 SCN9A (0.55) SCN9AKCNH2SCN5ASCN2ASCN10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250122172-A1 SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS DART NEUROSCIENCE LLC 2025-04-17 — — US disclosed
US-20230075774-A1 SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS DART NEUROSCIENCE LLC (US) 2023-03-09 — — US disclosed
US-11279691-B2 Substituted pyridine and pyrazine compounds as PDE4 inhibitors DART NEUROSCIENCE LLC (US) 2022-03-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250122172-A1 SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS PDE4A, PDE4B, PDE4D SCN9A 4227/4885KCNH2 2414/4885SCN5A 1839/4885
US-20230075774-A1 SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS PDE4A, PDE4B, PDE4D SCN9A 4227/4885KCNH2 2414/4885SCN5A 1839/4885
US-11279691-B2 Substituted pyridine and pyrazine compounds as PDE4 inhibitors PDE4A, PDE4B, PDE4D SCN9A 4198/4885KCNH2 2366/4885SCN5A 1777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback